Clinical Trial: Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07662031) titled 'Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer' on June 17.

Brief Summary: This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer Metastatic Colorectal Cancer

Intervention: BIOLOGICAL: Tovecimig

Tovecimig is provided in 10 mg/kg dose intravenously over the course of 60 minutes on Day 1 and Day 15 of a 28-day cycle.

DRUG: Irinotecan

Standard of care irinotecan will be...